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Abstract
This review summarizes phase I trial results of 11 drugs presented at the American Society of
Clinical Oncology meeting held in Chicago IL from May 30 to June 3rd 2008: BMS-663513, CT-322,
CVX-045, GDC-0449, GRN163L, LY2181308, PF-00562271, RAV12, RTA 402, XL765, and the
survivin vaccine.
Introduction
This year, a myriad of novel agents were introduced by
way of Phase I trials at the American Society of Clinical
Oncology (ASCO) meeting, held in Chicago, IL, from May
30 to June 3rd 2008. With the shift of drug development
from cytotoxic to targeted mechanisms of action, new and
exciting drug classes are being created; over 10 different
classes with first-in-human results were identified from
this year's meeting alone. These targeted agents, as com-
pared to traditional cytotoxic therapies, may have
decreased toxicity and unique pharmacokinetic profiles.
Furthermore, armed with pharmacodynamic assays that
measure successful inhibition of designated targets, these
phase I trial results suggest potential for using biomarkers
to help predict and monitor clinical response.
This discussion will focus on phase I results for eleven
first-in-class, first-in-human targeted agents: BMS-
663513, CT-322, CVX-045, GDC-0449, GRN163L,
LY2181308, PF-00562271, RAV12, RTA 402, XL765, and
the survivin vaccine. We have limited our discussion to
systemic therapies, although phase 1 results for two virus-
vector drugs that are injected directly into tumors, OBP-
301 and JX-594, were presented at ASCO as well [1,2].
The drugs discussed below are grouped by the cellular
location of their intended targets – cell surface, intra-cyto-
plasmic, or intra-nuclear. Some of these drugs inhibit
well-known targets by a novel mechanism, such as the
anti-angiogenic adnectins. Other drugs seek to alter the
milieu surrounding cancer cells and enhance anti-tumor
immunity, such as the antibody to CD-137 (BMS-
663513) and the antioxidant inflammation modulator
RTA 402. And finally, small-molecule drugs targeting tel-
omerase (GRN163L), survivin (LY2181308 and vaccine),
and the hedgehog pathway (GDC-0449) were presented
at ASCO this year, marking the culmination of intense
pre-clinical research over the past one to two decades for
these agents.
All of the drugs under discussion entered phase I trials
because of demonstration of anti-tumor effect in vitro and
in xenograft animal models. Most of the phase I studies
incorporated a standard 3 + 3 dose escalation design,
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where 3 to 6 patients were treated per dose level [3].
Patient characteristics were typical for phase I clinical tri-
als-all patients had good performance status (ECOG 1 or
better), and most patients were heavily pre-treated with
standard drug regimens before enrollment. The anti-ang-
iogenic drug trials also excluded patients with intracranial
masses, uncontrolled hypertension, and other factors that
increased bleeding risk. Dose-limiting toxicities (DLT)
were typically defined as grade 3 or worse non-hemato-
logical, or grade 4 or worse hematological adverse events,
at least possibly related to study drug, occurring within a
specified time period after drug delivery, although varia-
tions of DLT definitions may exist based on anticipated
toxicity from preclinical data. Maximum tolerated dose
(MTD) was generally defined as the dose level just below
the one at which an unacceptable number of DLTs were
encountered (usually > 1/3 or 2/6 of patients), and this
dose is typically the recommended phase II dose in most
phase I trials. Finally, although evaluation of clinical effi-
cacy is not the purpose of phase I trials, the clinical out-
comes for patients enrolled in these trials is of major
interest and was presented for most drugs discussed
below.
Drugs that target cell surface moieties
BMS-663513, a CD-137 antibody
BMS-663513 is a fully humanized monoclonal antibody
agonist of CD-137, a tumor necrosis factor (TNF)-receptor
that is expressed on the surfaces of activated white blood
cells. Stimulation of CD-137 enhances immune response,
specifically an anti-tumor immune response, by a variety
of mechanisms [4]. Phase I and II data presented by M.
Sznol et al. focused initially only on melanoma patients
(23 patients in phase I) but expanded to add renal cell car-
cinoma and ovarian cancer patients (30 enrolled per
tumor site in phase II) [5].
The antibody was extremely well tolerated with no MTD
reached; only 6% of patients developed grade 3 or higher
neutropenia, 15% grade 3 or higher increased liver
enzymes. Mild fatigue, rash, pruritis, diarrhea, and fever
were observed in up to 15% of patients, with only a few
instances of grade 3 or higher fatigue or fever (NB associ-
ation of fever with neutropenia was not made in the pres-
entation). Toxicity was not related to dose level of drug
(ranging from 0.3 mg/kg to 15 mg/kg every 3 weeks).
Partial responses were limited to only 6% of the
melanoma patients, although 17% of melanoma patients
and 14% of renal cell patients had stable disease at 6
months or longer. Pharmacodynamic studies of blood
showed increased levels of activated CD8 cells on day 8
post-treatment, however the increase in CD8 levels, as
well as blood levels of other immunologic biomarkers,
did not correlate with clinical outcomes.
A phase II clinical trial using BMS-663513 as 2nd line
treatment for patients with metastatic melanoma has
opened [6]. Presumably since no MTD or recommended
phase II dose was found by Sznol et al., this study will be
testing different doses of BMS-663513 (ranging from 0.1
to 5 mg/kg every 3 weeks).
RAV12, antibody to RAAG12
RAV12 is a chimeric IgG1 antibody that targets RAAG12,
a carbohydrate moiety attached to cell surface proteins
(including many growth factor receptors). RAAG12 is
only expressed on epithelial cells lining the gastrointesti-
nal (GI) tract; immunohistochemistry studies reveal dif-
fuse membrane expression of RAAG12 in human GI
cancer cells. Binding of RAV12 to RAAG12 induces tumor
cell death via oncolysis (direct cell death); in preclinical
animal xenograft models only tumor cell lines expressing
RAAG12 (at least 10% of cells) demonstrated any
response [7].
Lewis et al. presented preliminary phase I data on 53
patients, most of whom had GI cancers (colon, pancreatic,
gastroesophageal) and all of whom demonstrated greater
than 10% expression of RAAG12 on tumor specimens
(whether these were original pathology specimens or
biopsies taken at start of trial was not specified) [8]. Tox-
icity in the form of liver enzyme elevation, abdominal dis-
comfort, and diarrhea was dose-limiting at the highest
dose initially tested (1.5 mg/kg weekly). Pharmacokinetic
profiling prompted a change from once-weekly dosing to
twice and three-times weekly dosing, to minimize peak
serum concentrations without compromising steady state
levels. After fractionating the dose, Grade 3 or higher liver
enzyme elevation was limited to less than 20% of
patients, and diarrhea of grade 3 or higher severity was
seen in less than 10% of patients. Immunogenicity to the
chimeric antibody was seen in 14% of patients, with one
anaphylactic reaction documented.
Out of 41 patients evaluated, 7 patients showed some evi-
dence of stable disease, 1 additional patient with pancre-
atic cancer had stable disease lasting greater than 5
months, and 1 other patient with colorectal cancer had
partial response lasting greater than 8 months. A phase II
study in combination with chemotherapy, at a dose of
0.75 mg/kg delivered twice weekly, has opened for pan-
creatic cancer patients and another phase II study is
planned for colorectal cancer patients.
CVX-045, an antiangiogenic fusion molecule
CVX-045 is a fully human monoclonal antibody fused to
two thrombospondin-1 (TSP-1) mimetic peptides. TSP-1
is a known inhibitor of angiogenesis [9], and attaching the
small TSP-1 peptide to an antibody not only preservesJournal of Hematology & Oncology 2008, 1:20 http://www.jhoonline.org/content/1/1/20
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anti-angiogenic properties but greatly extends the half-life
[10].
Mendelson et al. presented phase I results for 18 patients
with advanced solid tumors treated with CVX-045 in esca-
lating dose cohorts (0.3 up to 18 mg/kg) [10]. Dosing was
weekly, with radiologic assessment of response every 8
weeks and pharmacodynamic measurements of tumor
vascular permeability via dynamic contrast-enhanced
(DCE) MRI before treatment, day 2–4 after first infusion,
and day 29 in the higher dose cohorts.
No dose-limiting toxicities were encountered and no
immunogenicity to the drug was detected. However two
patients experienced serious adverse events attributed to
study drug: radiation pneumonitis and bowel obstruction
with perforation leading to death. Common mild side
effects included fatigue, gastrointestinal upset, dyspnea,
headache, dizziness, and anemia. One patient with color-
ectal cancer demonstrated partial response, and 33% of
patients showed stable disease that lasted at least 8 weeks
on treatment. DCE-MRI studies demonstrated some
changes in blood flow but no change in tumor vascular
permeability.
CT-322, an AdNectin™
Adnectins are a new class of targeted biologics, designed
after the ubiquitous protein fibronectin, but with altered
binding sites for specific cell-surface targeting. Sweeney et
al. presented phase I results for CT-322, a potent vascular
endothelial growth factor 2 (VEGFR-2) inhibitor, and the
first adnectin to be tested in humans [11]. Thirty-nine
patients with solid tumors or non-Hodgkin's lymphoma
were enrolled.
Common side effects included proteinuria and hyperten-
sion. Grade 3 proteinuria, reversible posterior leucoen-
cephalopathy syndrome, and retinal vascular occlusion
were DLTs that lead to an MTD of 2 mg/kg/week; the
authors did not specify whether 2 mg/kg/week would be
the recommended phase II dose. No infusion reactions
and no evidence of antibody formation to the drug were
observed. Stable disease in 49% of the 37 patients evalu-
ated was the best response, with a durable response of
greater than 12 months in one patient with signet ring car-
cinoma (unknown primary).
Pharmacodynamic response was measured by levels of
vascular endothelial growth factor A (VEGF-A), which has
been shown in pre-clinical studies to be increased when
VEGFR-2 is blocked [12]. VEGF-A levels did rise within 4
hours after drug injection and remained elevated for at
least 4 days post-injection. Higher levels of VEGF-A were
seen with increased doses, with a plateau reached at a dose
of 1 mg/kg/week.
A phase II clinical trial using CT-322 alone or in combina-
tion with irinotecan has opened for patients with recur-
rent gliobastome multiforme; the dose used in this trial
has not been specified [13].
GDC-0449, a hedgehog pathway antagonist
LoRusso et al presented phase I results of GDC-0449, an
oral small molecule inhibitor of Smoothened (SMO)
[14]. SMO is a transmembrane protein that localizes to
the cell membrane when hedgehog (Hh) ligands (Sonic,
Indian, or Desert Hh) bind to cell surface receptor
Patched1 (Ptch1). Surface localization of SMO initiates a
signaling cascade that leads to activation of glioma-associ-
ated (Gli) transcription factors [15]. The hedgehog path-
way normally directs organ development during
embryogenesis, but can be abnormally activated in cancer
cells, particularly in basal cell cancers (BCC) [16].
Three cohorts of patients, totaling 19, with a myriad of
solid tumors (containing at least 1 BCC patient per
cohort) were enrolled at 3 different dose levels – 150, 270,
and 540 mg. Pharmacokinetic data were obtained via a
unique dose schedule: first administered dose was day 1,
followed by a 2nd dose at day 8 with daily dosing
onwards. Half-life of the drug was long, between 10 to 14
days. Maximal drug concentration after a single dose of
drug was the same in the 270 and 540 mg cohorts, and
steady-state serum levels were the same in all three dose
cohorts, indicating pharmacodynamic 'futility' at doses
higher than 150 mg with this schedule.
Skin punch biopsies and hair follicles were used for phar-
macodynamic analysis. Down-modulation of Gli 1 tran-
scription factor was observed in all skin punch biopsy
samples after treatment with GDC-0449.
The drug was extremely well tolerated; drug-related
adverse events included grade 2 or less dysguesia in 16%
of patients, and grade 3 hyponatremia and fatigue in
10.5% and 5% of patients respectively, with no DLTs. Par-
tial disease response was seen in 2 patients with basal cell
carcinoma, and stable disease was observed in another 2
patients with adenocystic carcinoma. The two responding
BCC patients were reported to have a very durable
response, at 10 months and longer. Phase II studies are
now recruiting for GDC-0449 vs. placebo in combination
with chemotherapy and bevacizumab for first-line treat-
ment of metastatic colorectal cancer [17], and are being
planned for use of GDC-0449 in advanced BCC [14] and
as maintenance therapy after 2nd or 3rd remission in
ovarian cancer patients [18].Journal of Hematology & Oncology 2008, 1:20 http://www.jhoonline.org/content/1/1/20
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Drugs whose targets are intra-cytoplasmic
Survivin inhibitors
Survivin is a member of the inhibitor of apoptosis protein
(IAP) family, and has generated interest because of its
increased expression in many human cancer cell lines
[19]. This year at ASCO, two phase I studies of drugs that
target survivin, one through decreasing expression at the
mRNA level and the other via vaccination, were presented.
LY2181308 is a new 2'-O-methoxymethyl modified anti-
sense oligonucleotide (ASO) designed to inhibit survivin
mRNA expression [20]. Thirty-one patients with various
tumors including breast, colon, and melanoma, were
enrolled in a phase I study presented by Talbot et al, with
LY2181308 given as 3 consecutive daily 3-hour intrave-
nous loading doses followed by weekly maintenance
doses [21]. Fever, fatigue, nausea, and elevated partial
thrompoplastin times (PTT) were common side effects,
while headache was a DLT at the highest dose tested
(1000 mg). Pharmacokinetic profiles showed rapid clear-
ance of this intravenous drug after administration, con-
sistent with other second-generation ASOs.
Tumor biopsies were obtained in 23 patients pre-and
post-treatment to determine whether survivin expression
was decreased; preliminary immunohistochemistry
results showed drug penetration in to tumor and
decreased survivin levels in 6/12 analyzed pairs of tumor
biopsies. Further analysis of survivin gene expression in
these samples is planned. Clinical response has so far
been limited to stable disease in 10% of patients. A phase
II study of LY2181308 in combination with docetaxel
chemotherapy in prostate cancer patients has opened
[22].
Becker et al presented the phase I/II results of a survivin
peptide vaccine, administered to 79 patients, most of
whom had melanoma [23]. Three peptides designed for
HLA haplotypes A1, A2, and B35 were constructed;
patients received 1 to 3 of the peptides depending on hap-
lotype matches. Two dose schedules were tested: three ver-
sus six once-weekly injections followed by monthly
maintenance injections, with a third cohort receiving the
latter regimen after a single 250 mg/m2 dose of cyclo-
phosphamide.
Common low grade side effects included injection site
reactions, fever, and painless swelling of the lymph nodes
draining the vaccination sites. Immune responses to the
drug were observed in 50% of patients, with a trend to
higher response in the higher-frequency group. Only
patients that demonstrated immune response had any
clinical response; of the immune responders, 3 had com-
plete response and 3 had partial response lasting up to 36
months.
XL765, a dual PI3K and mTOR inhibitor
Phosphatidyl inositol-3-kinase (PI3K) and the mamma-
lian target of rapamycin (mTOR) are enzymes in a com-
mon shared pathway – PI3K activates mTOR through
another enzyme called AKT. The PI3K/AKT/mTOR path-
way is constitutively active in many cancer cells, and plays
a key role in cell survival, proliferation, and resistance to
chemotherapeutic and targeted agents [24]. PI3K, AKT,
and mTOR have been targeted individually by various
drugs, but XL765 is the first oral dual PI3K and mTOR
inhibitor with Phase I trial results, reported by Papa-
dopoulos et al [25].
Nineteen patients with solid tumors were enrolled and
dosing ranged from 15 to 120 mg administered twice
daily (bid), with 28-day cycle length. Patients with diabe-
tes or hyperglycemia were excluded from this trial.
Transaminitis, diarrhea, anorexia, and fatigue were com-
mon mild side effects, with transaminitis and anorexia
becoming dose-limiting grade 3/4 toxicities at 120 mg
bid; therefore 60 mg bid was chosen as the MTD, although
the phase II dose has yet to be decided since additional
patients will be enrolled in a once daily dosing schedule.
Pharmacodynamic studies included measurement of
plasma insulin levels, since PI3K is also crucial to insulin
signaling and its attenuation contributes to type II diabe-
tes [26]. XL765 raised plasma insulin levels in a dose-
dependent manner, although grade 1 hyperglycemia was
noted in only one patient. Hair samples, skin punch biop-
sies, and tumor biopsies obtained before and after drug
administration demonstrated decreased phosphorylation
of various targets in the PI3K pathway, including AKT.
Ki67, a marker of proliferation, was also found to be
reduced in some tumor biopsy specimens. Best responses
to this drug are stable disease lasting at least 3 months in
5 patients, 2 of whom had sustained response for longer
than 6 months (one mesothelioma patient and one colon
cancer patient).
PF-00562271, a focal adhesion kinase inhibitor
Focal adhesion kinase (FAK) is a non-receptor protein
tyrosine kinase located in the cytoplasm at focal adhe-
sions – sites that link the extracellular matrix to the cyto-
plasmic cytoskeleton. Not only do FAKs therefore play a
pivotal role in cell migration, but they also influence cell
survival and are upregulated in a broad spectrum of epi-
thelial cancers [27]. PF-00562271 is an oral reversible
inhibitor of FAK, and phase I results for this drug were pre-
sented [28].
Sixty-six patients with solid tumors were enrolled and
received between 5 mg to 225 mg total daily dose, with
scheduling either daily or bid and either fasting or fed,
administered in 21-day cycles. Common low-grade sideJournal of Hematology & Oncology 2008, 1:20 http://www.jhoonline.org/content/1/1/20
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effects included nausea, vomiting, diarrhea, headache,
fatigue, dizziness, peripheral neuropathy, anorexia, and
edema. Headache and nausea/vomiting were dose-limit-
ing and helped define a recommended phase II dose of
125 mg bid (given with food).
Eleven patients (17%) had stable disease for more than 6
cycles. Positron emission tomography (PET) was used to
monitor pharmacodynamic response, with 6 patients
showing a 15% or more reduction in uptake of fluorode-
oxyglucose (FDG). Moreover, these 6 patients all attained
high steady-state serum concentrations of PF-00562271,
indicating that PET scanning as a bio-imager may accu-
rately reflect drug bioavailability and potentially clinical
response.
Drugs with intra-nuclear targets
GRN163L, a telomerase inhibitor
Telomerase maintains telomere length and its over-
expression in human cancer cells plays a key role in their
immortalization [29]. GRN163L is an oligonucleotide
that binds to the RNA active site of telomerase, thereby
inhibiting telomerase activity. Ratain et al. presented pre-
liminary toxicity data for patients with various solid
tumors in escalating dose cohorts of 0.4 to 4.8 mg/kg per
week [30]. Common adverse effects included PTT prolon-
gation, gastrointestinal side effects, fatigue, anemia, GGT
elevation, and peripheral neuropathy. One death from
unknown causes occurred at 3.2 mg/kg, and thrombocy-
topenia was a DLT at 4.8 mg/kg. Clinical efficacy data was
not available at the time of this report.
RTA 402, a triterpenoid
RTA 402 is an oral synthetic triterpenoid that inhibits
transcription factors NF-κB (nuclear factor-kappa B) and
the STAT3 (Signal Transducers and Activators of Tran-
scription protein 3) [31,32]. These transcription factors
have gene targets that promote cancer cell proliferation
and suppress anti-tumor immunity [33,34]. In addition,
RTA 402 induces nuclear erythroid 2 p45 related factor
(Nrf-2)-mediated transcription of antioxidant proteins
which helps suppress tumor proliferation [35].
Hong et al presented results of a phase I study in which 47
patients, 16 of which had melanoma, were enrolled with
RTA 402 dosed daily for 21 consecutive days out of a 28
day cycle [36]. The drug was extremely well tolerated with
only 4% or less of patients experiencing grade 3 nausea or
fatigue; other side effects included anorexia, diarrhea, and
dysguesia. Grade 3 ALT elevation was the DLT at 1300 mg/
day, thus 900 mg/day was chosen as the MTD and recom-
mended phase II dose. Pharmacokinetic studies showed
that RTA 402 has a long half-life of 39 hours.
Clinical responses were encouraging: of 30 evaluable
patients, 40% had stable disease, while one patient with
mantle cell lymphoma had a complete response and one
with anaplastic thyroid cancer had a partial response.
Responses were durable with 50% of responders remain-
ing on drug for 6 months or longer; stable disease
responders consisted of patients with melanoma, renal
cell, and medullary thyroid cancers.
Biopsies of tumor at days 1 and 21, performed in 5
patients, confirmed inhibition of NF-κB, STAT3 and their
target cyclin D1 levels, as well as induction of Nrf2. Inter-
estingly, almost half of the patients who achieved stable
disease on drug had peripheral leukocytosis and throm-
bocytosis, lending weight to the hypothesis that RTA 402
enhances anti-tumor immunity. Phase II studies are being
planned in pancreatic cancer (combined with gemcitab-
ine), and in combination with chemotherapy in
melanoma patients.
Discussion
Phase I trials of targeted agents represent the culmination
of years of laboratory work and preclinical animal evalua-
tions. Therefore the results are met with excitement and
trepidation: excitement for possible clinical benefits and
trepidation that the adverse effects of the drug preclude
any further development.
Fortunately, the drugs presented this year at ASCO seem
to dispel concern regarding toxicity – most were tolerated
very well, and only two deaths attributable to the drugs
were reported from amongst all eleven of the studies
included in this review. In fact, MTDs were not reached for
BMS-663513, CVX-045, and GDC-0449, which is unlikely
to occur with traditional cytotoxic chemotherapeutics.
Choice of appropriate dose for phase II studies therefore
relies on other measures; for example the pharmacokinet-
ics of the oral agent GDC-0449 indicated that steady-state
plasma concentrations were equal among all doses tested,
therefore the lowest was chosen for phase II trials. In con-
trast, BMX-663513, an antibody whose plasma levels did
correlate with increasing dose, but where side effects and
response seemed to be independent of dosing, is going
forward to phase II clinical trials at different dose levels to
help further determine the ideal dose.
The targeted agents presented this year also demonstrate a
paradigm shift that is revolutionizing the treatment of
cancer – the use of biomarkers to select individual thera-
pies for individual patients. Even from these preliminary
phase I trials, where toxicity and dose-finding are the pri-
mary goals, interesting pharmacodynamic data were col-
lected. For example, patient selection for the RAV12
antibody was limited to those patients whose tumor spec-
imens demonstrated at least 10% expression of its targetJ
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Table 1: Summary of eleven first-in-human drugs presented at this year's ASCO meeting.
Drug name Target Route Tumor sites 
enrolled
Common low-grade 
adverse effects
Dose-limiting 
toxicities
RPTD Clinical 
efficacy
Phase II studies 
planned/o pen
BMS-663513 CD-137 agonist i.v. Melanoma Renal cell 
Ovarian
Fatigue
Rash/pruritis
Diarrhea
Fever
Neutropenia
Transaminitis
TBD (range from 0.1–5 mg/
kg every 3 weeks)
6% PR 15% SD† Melanoma
CT-322 VEGFR-2 i.v. Misc. solid tumors 
and NHL
Proteinuria
Hypertension
Proteinuria
RPLS
Retinal vascular 
occlusion
MTD of 2 mg/kg/week, 
RPTD not specified
49% SD† GBM
CVX-045 Thrombospondin i.v. Misc. solid tumors Fatigue
GI
Dyspnea
Headache
Dizziness
None
1 radiation 
pneumonitis
1 death 
(bowel obstruction)
12 mg/kg/week 5% PR 33% SD TBD
GDC-0449 Smoothened oral Misc. solid tumors Dysguesia
Hyponatremia
Fatigue
None 150 mg daily 11% PR
11% SD
Colorectal
Ovarian
BCC
GRN163L Telomerase i.v. Misc. solid tumors Prolonged PTT
GI
Fatigue
Thrombocytopenia
One death 
(unknown cause)
TBD TBD TBD
LY2181308 Survivin i.v. Misc. solid tumors Fever
Fatigue
Prolonged PTT
Nausea
Headache 750 mg daily for 3 days, 
then weekly
10% SD ProstateJ
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PF-00562271 FAK oral Misc. solid tumors GI
Headache
Fatigue
Dizziness
Headache
Nausea
125 mg twice daily 17% SD TBD
RAV12 RAAG12 i.v. GI cancers Diarrhea
Abdominal discomfort
Transaminitis
Diarrhea
Abdominal 
discomfort
Transaminitis
0.75 mg/kg twice weekly 2% PR 20% SD† Pancreas
Colorectal
RTA 402 NF-κB and 
STAT3
oral Misc. solid tumors 
and NHL
GI
Fatigue
Anorexia
Dysguesia
ALT elevation 900 mg/day 7% CR + PR
40% SD†
Pancreas
Melanoma
XL765 PI3K and mTOR oral Misc. solid tumors Transaminitis
Diarrhea
Anorexia
Fatigue
Transaminitis
Diarrhea
Possibly 60 mg twice daily 26% SD TBD
Survivin 
vaccine
Survivin s.c. Melanoma Injection site reactions
Fever
Lymph node swelling
None TBD 8% CR+PR TBD
†Clinical efficacy was not available at time of presentation for all patients enrolled in these studies, therefore these response rates do not represent the whole study cohort and may change in the future
Abbreviations: TBD – to be determined; MTD – maximum tolerated dose; RPTD – recommended phase II dose; CR – complete response; PR – partial response; SD – stable disease; i.v. – intravenous; Misc 
– miscellaneous; NHL – non-Hodgkin's lymphoma; GBM – gliobastome multiforme; PTT – partial thromboplastin time; s.c. – deep subcutaneous; GI – gastrointestinal (including all 3 of nausea/vomiting/
diarrhea); BCC – basal cell carcinoma; RPLS – Reversible posterior leucoencephalopathy syndrome
Table 1: Summary of eleven first-in-human drugs presented at this year's ASCO meeting. (Continued)Journal of Hematology & Oncology 2008, 1:20 http://www.jhoonline.org/content/1/1/20
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RAAG12, although what proportion of total screened gas-
trointestinal cancer patients showed this level of expres-
sion was not presented and would be of interest.
Monitoring of downstream pathways of drug targets was
also presented for many of these new agents, again repre-
senting potential for predicting clinical response and for
proving mechanisms of action. Serum levels of activated
CD8 cells and VEGF-A increased after administration of
BMS-663513 and CT-322, respectively, as expected by the
drugs' mechanisms of action. Tumor biopsies after admin-
istration of LY2181308 and RTA 402 confirmed inhibi-
tion of their respective targets: survivin and the
transcription factors NF-κB and STAT3. Skin punch biop-
sies were used to illustrate down-regulation of Gli1, a
transcription factor activated by SMO, the target of GDC-
0449. Hair, skin, and tumor biopsies showed decreased
phosphorylation of many products downstream from the
PI3K/mTOR pathway inhibited by XL765. DCE-MRI
showed modified blood flow within tumors after admin-
istration of the anti-angiogenic fusion molecule CVX-045,
and PET scanning suggested a correlation between tumor
response and steady state serum levels of PF-00562271.
None of these phase I trials, except for BMS-663513 and
PF-00562271, attempted to correlate pharmacodynamic
studies with clinical response, but hopefully phase II stud-
ies may expand upon some of these potential predictive
markers in more homogeneous patient populations.
Although Phase I studies are not designed to evaluate clin-
ical efficacy these results are of interest. Of the eleven
drugs discussed, ten had clinical efficacy data available,
and of these ten all showed, at the very least, some stable
disease responders. A number of phase II studies have
already opened, encompassing such tumor sites as color-
ectal cancer, melanoma, gliobastome multiforme, and
prostate cancer. Table 1 summarizes the important clini-
cal findings of the eleven drugs discussed above.
In summary, phase I trial results for eleven first-in-human,
first-in-class targeted drugs hold promise for future clini-
cal applications. Toxicity was acceptable for all the drugs,
and clinical efficacy, although premature, shows poten-
tial. Pharmacodynamic analyses demonstrate that these
targeted agents actually do target the desired pathway of
interest, and may be useful for future biomarker applica-
tions. Phase II studies are underway for many of these
drugs in a broad array of tumor sites and will hopefully
translate into meaningful clinical results. Certainly, the
area of oncology therapeutics is burgeoning; a recent anal-
ysis demonstrated that between the years 2005 and 2007,
oncology trials comprised the largest therapeutic area
enrolled in the US Clinical Trials database, with the most
early phase clinical trials as well [37]. This year's ASCO
and its multiple first-in-human agents entering the clini-
cal arena is a further confirmation of this phenomenon.
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